{"id":5546,"date":"2025-10-23T13:56:02","date_gmt":"2025-10-23T13:56:02","guid":{"rendered":"https:\/\/regenerated.health\/migraine-treatment-options\/"},"modified":"2026-03-31T12:51:54","modified_gmt":"2026-03-31T12:51:54","slug":"migraine-treatment-options","status":"publish","type":"post","link":"https:\/\/regenerated.com\/blog\/migraine-treatment-options\/","title":{"rendered":"Migraine Treatment: Medications, Preventives, and Regenerative Options"},"content":{"rendered":"\n<div class=\"at-a-glance\">\n<h2>At a Glance<\/h2>\n<ul>\n<li>Triptans remain the gold standard for acute migraine, but CGRP antagonists (gepants) offer a new option<\/li>\n<li>Anti-CGRP monoclonal antibodies reduce migraine days by 50% or more in many patients<\/li>\n<li>Preventive treatment is recommended when migraines occur 4+ days\/month<\/li>\n<li>Neuromodulation devices (sTMS, Cefaly, gammaCore) provide drug-free alternatives<\/li>\n<li>Overusing acute medications (more than 10-15 days\/month) causes medication overuse headache<\/li>\n<\/ul>\n<\/div>\n\n<h2>Acute Treatment: Stopping an Attack<\/h2>\n\n<p>The goal of acute treatment is to make the migraine go away within 2 hours and keep it from coming back within 24 hours. Timing matters enormously: treating early (within the first hour of headache onset) dramatically improves response rates for nearly every medication class [1].<\/p>\n\n<h3>Triptans<\/h3>\n\n<p>Triptans are serotonin 5-HT1B\/1D agonists that work by constricting dilated blood vessels and blocking pain signal transmission in the trigeminovascular system. Seven triptans are available, and they are not interchangeable: patients who fail one may respond well to another [2].<\/p>\n\n<table>\n<thead>\n<tr><th>Triptan<\/th><th>Onset<\/th><th>Key Characteristics<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td>Sumatriptan (Imitrex)<\/td><td>30-60 min oral, 10 min SC<\/td><td>Most studied; available as oral, nasal spray, subcutaneous injection<\/td><\/tr>\n<tr><td>Rizatriptan (Maxalt)<\/td><td>30-45 min<\/td><td>Fast onset; orally dissolving tablet (ODT) form. Dose adjustment with propranolol<\/td><\/tr>\n<tr><td>Zolmitriptan (Zomig)<\/td><td>30-45 min<\/td><td>Available as nasal spray (bypasses GI absorption issues during nausea)<\/td><\/tr>\n<tr><td>Eletriptan (Relpax)<\/td><td>30-60 min<\/td><td>Highest 2-hour response rate in head-to-head studies. CYP3A4 metabolized<\/td><\/tr>\n<tr><td>Almotriptan (Axert)<\/td><td>60-90 min<\/td><td>Best tolerated; lowest rate of chest symptoms<\/td><\/tr>\n<tr><td>Naratriptan (Amerge)<\/td><td>60-120 min<\/td><td>Slowest onset but longest half-life; lowest recurrence rate. Good for menstrual migraine<\/td><\/tr>\n<tr><td>Frovatriptan (Frova)<\/td><td>120-180 min<\/td><td>Longest half-life (26 hours). Best for menstrual migraine prevention (taken perimenstrually)<\/td><\/tr>\n<\/tbody>\n<\/table>\n\n<p>Triptans are contraindicated in uncontrolled hypertension, coronary artery disease, history of stroke, and hemiplegic migraine. These contraindications exclude a significant number of patients, which is where gepants fill the gap.<\/p>\n\n<h3>Gepants (CGRP Receptor Antagonists)<\/h3>\n\n<p>Small-molecule CGRP antagonists that block the same pathway as anti-CGRP monoclonal antibodies but in oral form for acute use.<\/p>\n\n<ul>\n<li><strong>Ubrogepant (Ubrelvy):<\/strong> 50-100 mg oral. 2-hour pain freedom in 19-22% (vs. 12% placebo). No cardiovascular contraindications [3].<\/li>\n<li><strong>Rimegepant (Nurtec ODT):<\/strong> 75 mg orally dissolving tablet. Dual-approved for both acute treatment and prevention (every other day dosing). 2-hour pain freedom in 21%.<\/li>\n<li><strong>Zavegepant (Zavzpret):<\/strong> 10 mg nasal spray. Fastest onset gepant. 2-hour pain freedom in 24%. Good option when nausea prevents oral medication.<\/li>\n<\/ul>\n\n<p>Gepants lack the vasoconstrictor properties of triptans, making them safe for patients with cardiovascular disease. They also do not appear to cause medication overuse headache with regular use.<\/p>\n\n<h3>Ditans (5-HT1F Agonists)<\/h3>\n\n<ul>\n<li><strong>Lasmiditan (Reyvow):<\/strong> 50-200 mg oral. Works on the same serotonin pathway family as triptans but without vasoconstriction. Effective for triptan non-responders. Main limitation: CNS side effects (dizziness, sedation). Classified as Schedule V; patients cannot drive for 8 hours after dosing [4].<\/li>\n<\/ul>\n\n<h3>NSAIDs and Combination Analgesics<\/h3>\n\n<p>For mild-to-moderate migraines:<\/p>\n<ul>\n<li><strong>Ibuprofen 400-800 mg:<\/strong> Effective for mild attacks; best taken at onset<\/li>\n<li><strong>Naproxen 500-750 mg:<\/strong> Longer half-life provides sustained relief<\/li>\n<li><strong>Aspirin-acetaminophen-caffeine (Excedrin Migraine):<\/strong> OTC combination with good evidence for mild-moderate attacks. Caffeine enhances absorption and has independent analgesic properties<\/li>\n<li><strong>Diclofenac potassium 50 mg:<\/strong> Faster absorption than diclofenac sodium; good migraine-specific evidence<\/li>\n<\/ul>\n\n<h3>Anti-Emetics<\/h3>\n<p>Nausea and vomiting accompany many migraine attacks and impair oral medication absorption. Metoclopramide (10 mg) or prochlorperazine (10 mg) given IV or IM are effective both as anti-emetics and as migraine-specific treatments in the emergency department. Ondansetron (Zofran) addresses nausea but lacks direct migraine efficacy.<\/p>\n\n<h2>Preventive Treatment: Reducing Attack Frequency<\/h2>\n\n<p>Prevention is recommended when [5]:<\/p>\n<ul>\n<li>Migraines occur 4 or more days per month<\/li>\n<li>Acute treatments are ineffective or poorly tolerated<\/li>\n<li>Acute medication use exceeds 10-15 days per month (medication overuse threshold)<\/li>\n<li>Attacks are severely debilitating regardless of frequency<\/li>\n<li>Hemiplegic migraine, brainstem aura, or prolonged aura is present<\/li>\n<\/ul>\n\n<h3>Anti-CGRP Monoclonal Antibodies<\/h3>\n\n<p>The most significant advance in migraine prevention in decades. These injectable antibodies target CGRP or its receptor, providing sustained prevention with monthly or quarterly dosing.<\/p>\n\n<ul>\n<li><strong>Erenumab (Aimovig):<\/strong> 70-140 mg SC monthly. Targets the CGRP receptor. 50% migraine day reduction in 43-50% of patients. Most common side effect: constipation [6].<\/li>\n<li><strong>Fremanezumab (Ajovy):<\/strong> 225 mg monthly or 675 mg quarterly. Targets CGRP ligand. Quarterly option is unique to this agent.<\/li>\n<li><strong>Galcanezumab (Emgality):<\/strong> 240 mg loading dose, then 120 mg monthly. Targets CGRP ligand. Also approved for episodic cluster headache.<\/li>\n<li><strong>Eptinezumab (Vyepti):<\/strong> 100-300 mg IV quarterly. Fastest onset of any preventive (effect detectable on day 1 after infusion). The only IV anti-CGRP option.<\/li>\n<\/ul>\n\n<p>These agents have minimal systemic side effects and no drug interactions. They are not hepatotoxic and do not require blood monitoring. The main barrier is cost: $600-800\/month without insurance, though manufacturer patient assistance programs cover many patients.<\/p>\n\n<h3>Oral Preventives (First-Generation)<\/h3>\n\n<table>\n<thead>\n<tr><th>Medication<\/th><th>Daily Dose<\/th><th>Key Points<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td>Topiramate (Topamax)<\/td><td>50-200 mg<\/td><td>Strong evidence; causes weight loss. Cognitive side effects (&#8220;dopamax&#8221;), kidney stones, paresthesias<\/td><\/tr>\n<tr><td>Propranolol<\/td><td>80-240 mg<\/td><td>Beta-blocker; good for migraine + anxiety\/hypertension. Fatigue, exercise intolerance<\/td><\/tr>\n<tr><td>Amitriptyline<\/td><td>25-75 mg<\/td><td>Tricyclic antidepressant; helpful for migraine + insomnia or tension-type overlap. Weight gain, sedation<\/td><\/tr>\n<tr><td>Venlafaxine<\/td><td>75-150 mg<\/td><td>SNRI; useful for migraine + depression\/anxiety. Better weight profile than amitriptyline<\/td><\/tr>\n<tr><td>Valproate<\/td><td>500-1500 mg<\/td><td>Strong evidence; teratogenic (Category X). Weight gain, hair loss, hepatotoxicity risk<\/td><\/tr>\n<tr><td>Candesartan<\/td><td>8-16 mg<\/td><td>ARB; well tolerated. Good evidence from Scandinavian trials. Useful for migraine + hypertension<\/td><\/tr>\n<\/tbody>\n<\/table>\n\n<h3>OnabotulinumtoxinA (Botox)<\/h3>\n\n<p>Approved for chronic migraine (15+ headache days\/month). Thirty-one fixed-site injections across the head and neck every 12 weeks. Reduces headache days by an average of 8-9 per month. Takes 2-3 treatment cycles to reach full effect. Well tolerated; main side effects are injection site pain and neck weakness [7].<\/p>\n\n<h3>Neuromodulation Devices<\/h3>\n\n<p>FDA-cleared devices that modulate pain pathways without drugs:<\/p>\n<ul>\n<li><strong>Cefaly (external trigeminal nerve stimulation):<\/strong> Worn on the forehead; approved for both acute and preventive use. Reduces migraine days by 2-3 per month.<\/li>\n<li><strong>SpringTMS\/sTMS (single-pulse transcranial magnetic stimulation):<\/strong> Handheld device applied to the back of the head. Can abort aura and treat acute attacks.<\/li>\n<li><strong>gammaCore (non-invasive vagus nerve stimulation):<\/strong> Applied to the neck; approved for cluster headache and migraine. Modulates trigeminal pain processing.<\/li>\n<li><strong>Nerivio:<\/strong> Remote electrical neuromodulation worn on the upper arm; controlled via smartphone app. FDA-cleared for acute and preventive use.<\/li>\n<\/ul>\n\n<h2>Supplements with Evidence<\/h2>\n\n<p>Several supplements have level B evidence (probably effective) from the American Academy of Neurology [8]:<\/p>\n\n<ul>\n<li><strong>Magnesium:<\/strong> 400-600 mg\/day of glycinate, citrate, or oxide. Reduces cortical excitability. Particularly helpful in menstrual migraine and migraine with aura.<\/li>\n<li><strong>Riboflavin (B2):<\/strong> 400 mg\/day. Improves mitochondrial energy metabolism. Takes 3 months for full effect.<\/li>\n<li><strong>CoQ10:<\/strong> 100 mg three times daily. Mitochondrial cofactor. Evidence from a 2005 RCT showing 48% reduction in attack frequency.<\/li>\n<li><strong>Feverfew:<\/strong> 50-300 mg\/day of standardized extract. Anti-inflammatory via inhibition of prostaglandin synthesis. Mixed evidence but generally safe.<\/li>\n<li><strong>Butterbur (Petasites):<\/strong> Previously recommended but withdrawn in many markets due to hepatotoxicity concerns from PA (pyrrolizidine alkaloid) contamination. Only use PA-free certified products if considering.<\/li>\n<\/ul>\n\n<h2>Medication Overuse Headache: The Hidden Trap<\/h2>\n\n<p>Using acute migraine medications more than 10-15 days per month causes a paradoxical increase in headache frequency called medication overuse headache (MOH). All acute medications can cause it, but opioids and combination analgesics (butalbital) have the highest risk [9].<\/p>\n\n<p>Treatment requires withdrawal of the overused medication, which causes a temporary worsening (1-2 weeks of increased headaches) before improvement. Bridge therapy with a short course of corticosteroids, naproxen, or gepants helps manage the withdrawal period. Simultaneously starting a preventive medication is essential.<\/p>\n\n<h2>Emerging and Regenerative Approaches<\/h2>\n\n<ul>\n<li><strong>Nerve blocks:<\/strong> Greater occipital nerve (GON) blocks with local anesthetic and corticosteroid provide 2-4 weeks of relief. Useful as a bridge while preventive medications take effect.<\/li>\n<li><strong>Trigger point injections:<\/strong> Targeting myofascial trigger points in the cervical and trapezius musculature can reduce migraine frequency in patients with cervicogenic components.<\/li>\n<li><strong>Sphenopalatine ganglion (SPG) blocks:<\/strong> Intranasal lidocaine applied to the SPG can abort acute attacks. SPG stimulation devices are in clinical trials for cluster headache and migraine.<\/li>\n<li><strong>Psilocybin:<\/strong> Phase 2 clinical trials are investigating psilocybin for cluster headache and intractable migraine. Preliminary data suggests potential disease-modifying effects through serotonergic pathway modulation [10].<\/li>\n<li><strong>Ketamine:<\/strong> IV ketamine infusions are being explored for refractory chronic migraine, targeting NMDA receptor-mediated central sensitization.<\/li>\n<\/ul>\n\n<h2>Building a Treatment Plan<\/h2>\n\n<ol>\n<li><strong>Track first:<\/strong> Keep a headache diary for 1-2 months to establish baseline frequency, severity, and triggers<\/li>\n<li><strong>Optimize acute treatment:<\/strong> Find an effective acute medication and take it early. Avoid opioids and butalbital.<\/li>\n<li><strong>Start prevention if indicated:<\/strong> Choose based on comorbidities, side effect profile, and patient preference<\/li>\n<li><strong>Add supplements:<\/strong> Magnesium + riboflavin + CoQ10 as adjuncts<\/li>\n<li><strong>Address lifestyle factors:<\/strong> Regular sleep, exercise, hydration, stress management, trigger avoidance<\/li>\n<li><strong>Reassess every 3 months:<\/strong> Adjust or escalate as needed. Success = 50%+ reduction in migraine days.<\/li>\n<\/ol>\n\n<h2>Related Reading<\/h2>\n<ul>\n<li><a href=\"\/blog\/migraine\">Migraine: The Evidence-Based Guide<\/a> (Pillar)<\/li>\n<li><a href=\"\/blog\/migraine-aura\">Migraine with Aura: What It Looks Like and When to Worry<\/a><\/li>\n<li><a href=\"\/blog\/vestibular-migraine\">Vestibular Migraine: The Dizziness-Migraine Connection<\/a><\/li>\n<\/ul>\n\n<h2>References<\/h2>\n<ol>\n<li>Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? <em>Headache<\/em>. 1999;39(Suppl 2):S20-S26. doi:10.1111\/j.1526-4610.1999.00006.x<\/li>\n<li>Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: detailed results and methods of a meta-analysis. <em>Cephalalgia<\/em>. 2002;22(8):633-658. doi:10.1046\/j.1468-2982.2002.00404.x<\/li>\n<li>Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. <em>N Engl J Med<\/em>. 2019;381(23):2230-2241. doi:10.1056\/NEJMoa1813049<\/li>\n<li>Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. <em>Brain<\/em>. 2019;142(7):1894-1904. doi:10.1093\/brain\/awz134<\/li>\n<li>Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. <em>Neurology<\/em>. 2012;78(17):1337-1345. doi:10.1212\/WNL.0b013e3182535d20<\/li>\n<li>Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. <em>N Engl J Med<\/em>. 2017;377(22):2123-2132. doi:10.1056\/NEJMoa1705848<\/li>\n<li>Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. <em>Cephalalgia<\/em>. 2010;30(7):793-803. doi:10.1177\/0333102410364676<\/li>\n<li>Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. <em>Neurology<\/em>. 2012;78(17):1346-1353. doi:10.1212\/WNL.0b013e3182535d0c<\/li>\n<li>Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. <em>Neurology<\/em>. 2008;71(22):1821-1828. doi:10.1212\/01.wnl.0000335946.53860.1d<\/li>\n<li>Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory controlled study of the migraine-suppressing effects of psilocybin. <em>Neurotherapeutics<\/em>. 2021;18(1):534-543. doi:10.1007\/s13311-020-00962-y<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Migraine treatment has been transformed by CGRP-targeting drugs. Here&#8217;s the full landscape of acute, preventive, and emerging therapies.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","_regenerated_references":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-5546","post","type-post","status-publish","format-standard","hentry","category-health"],"_links":{"self":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/comments?post=5546"}],"version-history":[{"count":1,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5546\/revisions"}],"predecessor-version":[{"id":5695,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5546\/revisions\/5695"}],"wp:attachment":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media?parent=5546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/categories?post=5546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/tags?post=5546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}